22-Oct-2025	Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of NNZ-2591 in Children and Adolescents With Pitt Hopkins Syndrome

22-Oct-2025	Development of Clinician- and Caregiver-Reported Outcome Measures for Evaluating Pitt Hopkins Syndrome

26-Mar-2025	NNZ-2591, a Synthetic IGF-1 Metabolite Analog: Phase 2 Clinical Trial Results for Children and Adolescents With Pitt Hopkins Syndrome